Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Biora Therapeutics Inc

Biora Therapeutics, Inc. engages in the provision of molecular and specialized diagnostic tests to clinicians. Its products include the Preparent Carrier Test, Innatal Prenatal Screen, Riscover Hereditary Cancer Test, and Resura Prenatal Test. The company was founded by Paul W. Hawran and Harry Stylli in 2010 and is headquartered in San Diego, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Biora Therapeutics excels in therapeutics programs, secures strategic partnerships

Biora Therapeutics demonstrated strong performance in key programs, maintained financial stability, and expressed confidence in future prospects.
While facing challenges in device performance and operational planning, the company is well-positioned to capitalize on opportunities for growth and innovation.
Overall, Biora's focus on advancing therapeutic programs and strategic collaborations signals a positive trajectory for the company's future success.

Biora Therapeutics reports stable finances, progresses key drug programs

Biora Therapeutics showcased solid financial management with increased operating expenses but a stable cash position, while also securing additional funding for growth.
The company's focus on key programs and strategic collaborations, coupled with the appointment of a new Chief Medical Officer, bodes well for its clinical development efforts.
Despite challenges in managing expenses and optimizing capital structure, Biora's promising results and strategic initiatives offer opportunities for future growth and success in the pharmaceutical industry.

Biora Therapeutics advances drug delivery platforms and maintains financial stability

Biora Therapeutics showcased progress on innovative drug delivery platforms in Q2 2023. The company's financials remain stable, with a focus on disciplined cash management. Securing partnerships and advancing regulatory filings are key focus areas for future growth.

Biora Therapeutics reduces debt, advances key platforms amid financial challenges

Biora Therapeutics demonstrated financial progress alongside operational advancements in its NaviCap and BioJet platforms, despite facing increased expenses and a net loss for the quarter.
The company's focus on FDA clearance for BT-600 trial initiation and collaborations for the BioJet platform highlights its commitment to advancing innovative therapies and partnerships.
While challenges persist in financial management and collaboration coordination, Biora Therapeutics remains poised to leverage opportunities for growth and market expansion in the biopharmaceutical sector.

Biora Therapeutics excels in Q4 2023 with innovative drug technologies

Biora Therapeutics made significant strides in Q4 2023, advancing their platform technologies and strengthening their financial position. While facing challenges in clinical trials and market competition, the company is well-positioned to capitalize on opportunities for growth and partnerships in the coming year.

Biora Therapeutics advances drug delivery platforms, strengthens financial position

Biora Therapeutics' Q1 performance reflects a strategic focus on R&D, financial strength, and advancements in targeted drug delivery platforms.
The company faces challenges in optimizing partnerships and capital structure while balancing innovation and financial sustainability.
Opportunities lie in upcoming data releases, clinical studies, and partnerships to drive growth and market expansion in 2024.

Biora Therapeutics excels in Q2 with breakthrough drug delivery platforms

Biora Therapeutics' innovative drug delivery platforms show promise in revolutionizing ulcerative colitis treatment and advancing JAK inhibitor therapy.
The company's successful Phase I trial results and capital raise provide a strong foundation for future growth and partnership opportunities.
While challenges lie ahead in scaling up and navigating the competitive landscape, Biora's focus on breakthrough technologies positions them well for success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAN DIEGO, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced participation in a virtual fireside chat hosted by H.C. Wainwright & Co. on Monday, January 29, 2024 at 11:00 AM Eastern / 8:00 AM Pacific.

Biora Therapeutics Announces Participation in Fireside Chat Hosted by H.C. Wainwright & Co.

Biora anticipates 2024 catalysts, including clinical study results for NaviCap™ platform and progress on pharma partnerships for BioJet™ platform.

Biora Therapeutics Provides Outlook for 2024

First-in-human trial of BT-600 drug-device combination, following multiple successful device-only human studies SAD/MAD study to evaluate safety and PK/PD of BT-600, including concentrations in colon tissue SAN DIEGO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced initiation of its phase 1, first-in-human clinical study of BT-600 in healthy adult volunteers. BT-600 is a drug-device combination program consisting of the orally administered NaviCap™ device which delivers a unique, liquid formulation of tofacitinib to the colon for the potential treatment of moderate to severe ulcerative colitis.

Biora Therapeutics Announces Initiation of Phase 1 Clinical Study of BT-600

SAN DIEGO, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that its BioJet™ Systemic Oral Delivery Platform has met key performance milestones as part of its research collaboration with AstraZeneca. The BioJet platform is designed to use needle-free, liquid jet injection to deliver drug into the small intestine for systemic absorption.

Biora Therapeutics Progresses Research Collaboration for the BioJet™ Systemic Oral Delivery Platform

SAN DIEGO, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it received an Issue Notification from the U.S. Patent and Trademark Office for a patent related to the treatment of gastrointestinal (GI) disorders through targeted delivery of JAK inhibitors for its NaviCap™ targeted oral delivery platform under development. US Patent Application No.

Biora Therapeutics Announces New Patent for its NaviCap™ Targeted Oral Delivery Platform

Transaction results in nearly 60% reduction in net debt and brings $16 million in new capital; demonstrates investor confidence in near-term catalysts.

Biora Therapeutics Accelerates Debt Reduction and Raises Capital with Large Institutional Investors

SAN DIEGO, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced a new research collaboration with a large pharmaceutical company for its BioJet™ Systemic Oral Delivery Platform. The new agreement provides funding to test the BioJet platform's ability to achieve bioavailability through oral delivery of the undisclosed collaborator's molecules to the small intestine in animal models.

Biora Therapeutics Announces New Research Collaboration for the BioJet™ Systemic Oral Delivery Platform

BT-600 will deliver a proprietary liquid formulation of tofacitinib via the NaviCap™ device for topical delivery to the colon SAN DIEGO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application for BT-600, a drug/device combination for the treatment of moderate to severe ulcerative colitis. “The FDA has agreed with our plans to proceed with clinical development of BT-600 and has activated our IND application.

Biora Therapeutics Announces FDA Clearance of IND Application for Drug/Device Combination BT-600 Targeting Treatment of Ulcerative Colitis

Biora Therapeutics, Inc. (NASDAQ:BIOR ) Q3 2023 Earnings Conference Call November 13, 2023 4:30 PM ET Company Participants Chuck Pedala - LifeSci Advisors Adi Mohanty - CEO Eric d'Esparbes - CFO Conference Call Participants Joe Pantginis - H.C. Wainwright & Co. Julian Harrison - BTIG John Vandermosten - Zacks Investment Research Operator Greetings and welcome to the Biora Therapeutics Third Quarter 2023 earnings call.

Biora Therapeutics, Inc. (BIOR) Q3 2023 Earnings Call Transcript

NaviCap™ Targeted Oral Delivery platform advancing toward initiation of phase 1 clinical trial by year end Pharma collaborations accelerate for the BioJet™ Systemic Oral Delivery platform, which shows potential for liver-targeted delivery of large molecules Management will host conference call and webcast today at 4:30 PM Eastern / 1:30 PM Pacific SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today provided a corporate update and reported financial results for the third quarter ended September 30, 2023. “We took a big step in advancing our NaviCap platform toward the clinic, with the filing of our IND and a planned phase 1 trial for BT-600 on track for initiation in December,” said Adi Mohanty, Chief Executive Officer of Biora Therapeutics.

Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results

Biora will report financial results and provide a corporate update for the third quarter on on Monday, November 13, 2023, at 4:30 PM EST / 1:30 PM PST

Biora Therapeutics to Report Third Quarter 2023 Financial Results and Provide Corporate Update

NEW YORK , Nov. 3, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Biora Therapeutics, Inc. ("Biora" or the "Company") (NASDAQ: BIOR). Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biora Therapeutics, Inc. - BIOR

Update includes supplemental information and provides additional time to complete regulatory review; company expects to remain on track with Ph1 timeline.

Biora Therapeutics Submits Updated IND Application for BT-600

Update to include supplemental information and allow additional time for regulatory review. Biora anticipates remaining on track with ph1 trial timeline.

Biora Therapeutics to Submit Updated IND Application for BT-600

SAN DIEGO, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, presented data on oral delivery of a GLP-1 receptor agonist with its BioJet systemic oral delivery platform in a short oral discussion titled “Evaluation of the Pharmacokinetics of Glucagon-Like-Peptide-1 Receptor Agonist Delivered through the BioJet™ Biotherapeutic Delivery Platform in Swine” at the 59th annual meeting of the European Association for the Study of Diabetes, in Hamburg, Germany. “In recent studies, we assessed the bioavailability of semaglutide when delivered via our autonomous next-generation BioJet device in a porcine model.

Biora Therapeutics Presents Data on the BioJet™ Systemic Oral Delivery Platform at the 59th Annual Meeting of the European Association for the Study of Diabetes

BT-600 is a drug/device combination delivering a liquid formulation of tofacitinib via the NaviCap™ platform for the treatment of ulcerative colitis

Biora Therapeutics Announces Submission of IND Application to the U.S. FDA for BT-600 Program

ANGI Homeservices

Cemex SAB de CV

Every day the market offers us good investment opportunities with a variety of companies. While it can be hard work to investigate all investment opportunities on the market, in this article we can discover a great opportunity that we may not have found before.

Hidden Gems: 3 Penny Stocks Flying Under the Radar.

Funds managed by Athyrium Capital Management increase their equity exposure through a convertible notes exchange at a price representing a 44% premium to the closing price on September 18, 2023

Biora Therapeutics Reduces Debt and Largest Shareholder Increases Equity Exposure

SAN DIEGO, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced it will present at the upcoming H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023 in New York City.

Biora Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference

Confirmation of autonomous device function enables progress to testing of pharma collaborators' molecules Confirmation of autonomous device function enables progress to testing of pharma collaborators' molecules

Biora Therapeutics Progresses its BioJet™ Systemic Oral Delivery Platform

Biora Therapeutics, Inc. (NASDAQ:BIOR ) Q2 2023 Earnings Conference Call August 14, 2023 4:30 PM ET Company Participants Chuck Padala - Managing Director, LifeSci Advisors Adi Mohanty - Chief Executive Officer Eric d'Esparbes - Chief Financial Officer Conference Call Participants Joe Pantginis - H.C. Wainwright Julian Harrison - BTIG John Vandermosten - Zacks Investment Research Operator Greetings, and welcome to the Biora Therapeutics Second Quarter 2023 Earnings Call.

Biora Therapeutics, Inc. (BIOR) Q2 2023 Earnings Call Transcript

NaviCap™ targeted oral delivery platform on track for September IND filing; achieved successful device function study results in humans with phase 1-ready device

Biora Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results

Intellectual property relates to key features of the company's liquid jet injection technology Intellectual property relates to key features of the company's liquid jet injection technology

Biora Therapeutics Announces New Patents Covering its BioJet™ Systemic Oral Delivery Platform

SAN DIEGO, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that management will be attending the Canaccord Genuity 43rd Annual Growth Conference in Boston.

Biora Therapeutics to Participate in Canaccord Genuity 43rd Annual Growth Conference

Phase 1-ready device shows 100% success in human functional study of twelve subjects to date Phase 1-ready device shows 100% success in human functional study of twelve subjects to date

News for Biora Therapeutics Inc Stock (BIOR)